Navigation Links
Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
Date:2/6/2008

Results of VICTOR-E1 Phase II Study Presented at 15th Conference on

Retroviruses and Opportunistic Infections (CROI)

BOSTON, Feb. 6 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that final results of a Phase II clinical study showed vicriviroc, its investigational CCR5 antagonist, demonstrated potent and sustained viral suppression through 48 weeks of therapy in treatment- experienced HIV-infected patients, when administered once-daily as a single tablet in combination with an optimized ritonavir-boosted protease inhibitor containing antiretroviral regimen. Vicriviroc is a next-generation extracellular inhibitor of HIV infection designed to block entry of infectious virions into uninfected CD4 cells via antagonism of the CCR5 co-receptor.

Researchers reported the data in a late-breaker oral presentation at the 15th Conference on Retroviruses and Opportunistic Infections (CROI) on Feb. 4.

In the study, significantly more patients who added vicriviroc 30 mg once daily to a new optimized background therapy (OBT) had fully suppressed HIV-RNA (less than 50 copies/ml) at 48 weeks compared to patients receiving new OBT alone (56 percent vs. 14 percent, p=0.0002).

"These 48-week results demonstrate that vicriviroc added to OBT provides significant and durable viral suppression compared to OBT alone in this treatment-experienced HIV-infected patient population," said Barry S. Zingman, M.D., medical director - AIDS Center, Montefiore Medical Center and the Einstein/Montefiore Center for AIDS Research, and associate professor of clinical medicine, Albert Einstein College of Medicine, Bronx, N.Y., who presented the data. "Importantly, this benefit of vicriviroc was observed
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
3. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
4. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
5. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
6. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
7. New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
9. First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time
10. Study Shows Organons Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
11. US Preventive Medicine(R) Says Study on Heart Disease-related Deaths Demonstrates Need for Preventive Medical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ble in German . , One of the defining cha...ically prevent programmed cell death (apoptosis), ...iferation of defective cells. In order to do this,...) among other proteins. , Many of the cancer dr...Ps, since if the levels of IAPs are reduced, tumou...
(Date:12/1/2008)...AF,s National Legislative Team, Response to Issues..., WASHINGTON, Dec. 1 ... a national, non-profit organization dedicated to ...t access to healthcare through public policy refor...ay the appointment of Grayson Fowler to Vice Presi...
(Date:12/1/2008)...r orthopaedic surgeon is the driving force for a s...l., Dec. 1 /PRNewswire-USNewswire/ - - While many...ny musculoskeletal injury may be anxious to get ba... to get behind the wheel of a car can be a difficu...he concerns of orthopaedic surgeons and patients a...
(Date:12/1/2008)...ber 1 Mentice proudly announces,t...ulation training - the,Mentice VIST 7.7 enhanced ...ntions. New features such as vital signs, complica...tionality add to the clinical realism and,enhance... "Features like vital signs and complications...
Breaking Medicine News(10 mins):Health News:Surprise discovery made in cancer research 2Health News:National Patient Advocate Foundation (NPAF) Announces New Executive Vice President of Federal Legislative Affairs 2Health News:When to Get Back Behind the Wheel While on the Road to Recovery 2Health News:When to Get Back Behind the Wheel While on the Road to Recovery 3Health News:Mentice VIST(TM) New and Enhanced Carotid and Coronary Training Modules Take Medical Simulation Training to the Next Level 2
... who suffers from AIDS Wednesday inaugurated a uni...doms// as its theme. Pooja Thakur, who discovere...e in October 2005, said she was thrilled to be ina...- said to be the country's first. The unique bar...
...ow that older women - those 80 or older - have the...ng to new research// published today. Worryingly,... wrongly believed that age does not affect breast ... risk factor for breast cancer - after gender -is ...
...n optician who was part of a British charity, made...nteering// in India. Premal Patel, who was part o...y, carried out a record 850 eye examinations in a ...angalore in March. The charity helps people with ...
... autistic children are no more likely than other c... research. Researchers compared blood samples of ...without autism who had been referred to an outpati...looked for two antibodies used to help detect celi...
Other Medicine News:Health News:India’s First ‘condom Bar’ Inaugurated by AIDS Pati 2Health News:Women Unaware of When Breast Cancer Risk is Greatest 2
(Date:12/1/2008)...s still the best policy , , ROCHESTER, Min...from Mayo Clinic finds the use of the drug therapy...titis, an acute inflammation of the liver caused b... the study are published in the December issue of ... ). , , VIDEO ALERT: Additional audio and ...
(Date:12/1/2008)...RNewswire-FirstCall/ -- GeoVax Labs, Inc.,(OTC Bu...y company developing,human vaccines for diseases ...,other infectious agents, announced today that th...l take place in twelve sites across North and Sout...ation with The National Institutes of,Health (NIH...
(Date:11/28/2008)...any, November 28 German biotech co...n specialized HIV monitoring and,AIDS patient fol...ntries. In,the year 2008, 2.5 million patient tes...and highly affordable "CyFlow" system, supporting ...V/AIDS. Due to introduction of the,Partec innovat...
(Date:11/26/2008)...ion density, automation and intelligent clinical a... to an all new level , , CHICAGO, Ill., Nov...re ( www.siemens.com/healthcare ) highlights the...(ABVS)(1), the world,s first multi-use, automated...ntific Assembly and Annual Meeting of the Radiolog...
Breaking Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Bacteria successful in cancer treatment 621 1Bacteria successful in cancer treatment 621 2Siemens Extends Tender Offer for Acquisition of Dade Behring 619 1Siemens Extends Tender Offer for Acquisition of Dade Behring 619 2Actavis Launches Carvedilol Tablets in the U S 617 1Actavis Launches Carvedilol Tablets in the U S 617 2New knock out gene model provides molecular clues to breast cancer 615 1New knock out gene model provides molecular clues to breast cancer 615 2New knock out gene model provides molecular clues to breast cancer 615 3
... Tenn.--(BUSINESS WIRE)--May 25, 2007 - GTx, Inc.,... recent Phase II proof of,concept clinical trial o...ical trial evaluating ACAPODENE(R) (toremifene cit...ects of androgen,deprivation therapy (ADT) will be...the American Society of Clinical Oncology being,he...
..., Calif.--(BUSINESS WIRE)--May 24, 2007 - A new an...es are designed in ways,that inadvertently omit wo...Stanford University School of Medicine,researcher ... all,scientists that strict study eligibility crit...In reviewing data from a pool of 100,000 alcohol t...
Other Medicine Technology:GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3Limiting Eligibility for Medical Studies Can Omit Women,African-Americans, Stanford Study Finds 2Limiting Eligibility for Medical Studies Can Omit Women,African-Americans, Stanford Study Finds 3
The Infinity Amylase CPNG3 single liquid stable reagent offers the laboratory all the convenience of single liquid stability to help maximize laboratory productivity, minimize operator error and prov
The Infinity Urea single liquid stable reagent offers the laboratory all the convenience of single liquid stability to help maximize laboratory productivity, minimize operator error and provide quick
...t once reconstituted offers the laboratory all the...ximize laboratory productivity, minimize operator ...e proprietary technology of the Infinity Glucose H...e and stability once reconstituted that will minim...
The Infinity Amylase powder reagent once reconstituted offers the laboratory all the convenience of single liquid stability to help maximize laboratory productivity, minimize operator error and provi
Medicine Products: